Real Energy completes well stimulation at Tamarama-3

Published 05-OCT-2018 11:56 A.M.

|

1 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Real Energy (ASX:RLE) has informed the market that it has completed its four-stage fracture stimulation program at the Tamarama-3 well at below 2,300m depth.

Importantly, the company noted that operations on site were completed without any environmental or safety incidence.

RLE has finished its four-stage fracture program.

RLE noted that approximately 6,100 barrels of frac fluid was pumped, with 378,600 pounds of proppant injected into the formations over the course of the program.

Flow testing will be executed shortly and the flowback operation is expected to take several weeks once the majority of frac fluids are recovered from the formations.

RLE will release initial results upon their availability.

In addition, the company recently released footage of flow from its Tamarama 1 well, which may be watched via the following link: www.realenergy.com.au/tamarama

Of course this remains a speculative stock and investors should seek professional financial advice if considering this company for their portfolio.

About Real Energy

RLE is an oil and gas exploration and development company focusing on the Cooper Basin in Queensland, one of Australia’s most prolific onshore producing petroleum basins.

The company has 100% ownership in two large permits: ATP 927P & ATP1194A.

tags

OIL


General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X